Technology Melior Pharmaceuticals | Melior Affiliate Melior Pharmaceuticals leverages the proprietary technology if its affiliate company, Melior Discovery, to identify new indications for drugs that have existing clinical data in other indications Melior Discovery is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning
About Melior Pharmaceuticals | Clinical Stage Diabetes, NASH, Parkinson . . . Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of de-risked therapies in areas with significant unmet needs Our lead clinical stage candidates are in the areas of diabetes, NASH, Parkinson’s Disease and sleep disorders
MELIOR PHARMACEUTICALS ANNOUNCES EXECUTION OF LICENSE AGREEMENT FOR . . . July 29, 2021 Exton, PA – Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb) As with all of Melior’s drug candidates, MLR-1019 is a repositioned drug that has demonstrated
Mesocarb - Melior Pharmaceuticals Melior is now developing mesocarb in Parkinson’s disease levodopa induced dyskinesia, given compelling preclinical data in animal models of PD-LID: o Reduces levodopa induced dyskinesia in parkonsonian rats o Highly targeted approach; strong in vivo affinity and selectivity for DAT o Enhances anti-parkionsonian activity of levodopa activity
News Press Releases - Melior Pharmaceuticals Melior Pharmaceuticals Announces Entry Into "Letter-of-Intent" for the Acquisition of Armescarb by Adhera Therapeutics June 7, 2021 READ MORE DOWNLOAD PDF
MLR-1023 Phase 2B completion PR v10. 1 - Melior Pharmaceuticals May 14, 2019 Exton, PA – Melior Pharmaceuticals I, Inc (Melior) announced today that its novel first-in-class insulin sensitizer, tolimidone, has demonstrated significant reduction of HbA1c compared to placebo in a recently completed Phase 2B study involving patients with Type 2
Tolimidone A novel Phase 2b clinical stage drug candidate to treat Type . . . Melior Pharmaceuticals Inc is developing tolimidone, a Phase 2 clinical stage candidate for treatment of type 2 diabetes and metabolic disorders Tolimidone is a “next-generation” insulin sensitizer and lipid regulator that exerts its activity independently of the PPAR mechanism